The 3 best performing ASX shares of the week of 5 December 2022
Marc Kennis, December 12, 2022
The 3 best performing ASX shares in the week of 5 December 2022
The 3 best performing ASX shares of the week starting 5 December 2022 were Tombador Iron (ASX:TI1), up 38.1%, Macarthur Minerals (ASX:MIO), up 25%, and Cardiex (ASX:CDX), up 22.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Tombador Iron (ASX:TI1)
Industry: Resources
Our top 3 best performing ASX shares kicks off with Tombador Iron (ASX:TI1), which owns 100% of the fully permitted Tombador Iron Ore mine located in Bahia State Brazil. Tombador commenced production of premium-grade lump and fines hematite iron ore in May 2021 from a low-capex open-pit mining operation.
Market Cap: $62m
12 month high / low: $0.019 – $0.055
2. Macarthur Minerals (ASX:MIO)
Industry: Resources
Macarthur Minerals (ASX:MIO) is an iron ore development, gold and lithium exploration company that is focused on bringing to production its 100% owned Western Australia iron ore projects.
Market Cap: $33m
12 month high / low: $0.125 – $0.64
3. Cardiex (ASX:CDX)
Industry: Healthcare
Cardiex Limited (ASX:CDX) rounds out our top 3 best performing ASX shares this week. CDX is an ASX listed public company with operations in medical technology, wearable devices and telehealth, providing digital and device-based solutions for large-scale population health disorders with significant market scale. Its current focus is cardiovascular disease (CVD) and heart health.
Market Cap: $49m
12 month high / low: $0.25 – $0.72

No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.

Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
AMA Group (ASX:AMA) recovery is now being tested by whether cash flow can sustain the turnaround
AMA Group (ASX: AMA)’s recovery story is now being tested by whether improving earnings can translate into durable cash flow…
Radiopharm Theranostics (ASX: RAD) is increasingly defined by whether RAD101 can justify a registrational pathway
Radiopharm Theranostics (ASX:RAD) is increasingly defined by whether its lead imaging asset RAD101 can convert encouraging mid-stage data into a…
3P Learning (ASX:3PL) must arrest school churn to protect its valuation
3P Learning (ASX: 3PL)’s valuation now hinges on whether the business review can arrest B2B school churn and declining revenue…